MAP Infection-Associated Crohn’s Disease: RedHill Biopharma Shows Drug Potential

MAP Infection-Associated Crohn’s Disease: RedHill Biopharma Shows Drug Potential
RedHill Biopharma announced the publication of a peer-review article demonstrating the potential efficacy of RHB-104 for the treatment of Mycobacterium avium subspecies paratuberculosis (MAP) infection-associated Crohn’s disease. The article was authored by researchers from the Burnett School of Biomedical Sciences at the University of Central Florida (UCF) College of Medicine and titled “RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn's disease associated with Mycobacterium paratuberculosis.” The study was published in the journal Gut Pathogens. RHB-104 is a patented oral antibiotic combination therapy with strong properties at the intracellular, anti-mycobacterial and anti-inflammatory levels. RHB-104 was grounded on emerging evidence that supports the hypothesis that Crohn’s disease is caused by MAP infections in susceptible patients. The article describes a preclinical study designed to evaluate the efficacy of RHB-104 active components (antibiotics clarithromycin, clofazimine and rifabutin) against MAP strains isolated from Crohn’s patients’ blood, tissue and milk. The preclinical study’s results showed that the active components of RHB-104, individually or dually combined, were not as effective against all microorganisms as triple combinations at minimum inhibitory concentration levels. Based on the results, the research team co
Subscribe or to access all post and page content.

One comment

  1. CJ says:

    Another press release concerning the preconceived notion that CD is definitely caused by MAP- a contentious hypothesis at best. RHB’s most recent publication may demonstrate efficacy of killing MAP in a test tube, but whether stuffing Crohn’s sufferers full of abx for years on end will help them by curtailing hypothetical MAP infection or by simply clearcutting their gastrointestial microbiota remains to be seen. In all likelihood, RHB has no plans to demonstrate efficacy on MAP, but instead simply say “See! It had to have been MAP!” because they stuffed patients full of antibiotics.

Leave a Comment

Your email address will not be published. Required fields are marked *